Interventional treatment combined with immunotargeted therapy in unresectable combined hepatocellular-cholangiocarcinoma: a real-world retrospective cohort study

Interventional treatment combined with immunotargeted therapy in unresectable combined hepatocellular-cholangiocarcinoma: a real-world retrospective cohort study

BackgroundEvidence-based treatment for unresectable combined hepatocellular-cholangiocarcinoma (cHCC-CCA) has not been established. This study aimed to assess the effectiveness and safety of interventional treatment combined with immunotargeted therapy (IIT) in unresectable cHCC-CCA patients.Methods...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yan-Song Lin, Li-Yan Wu, Li-Hui Lin, Xia Yang, Fang-Yi Liu, Yan-Qin Wu, Zhen Ding, Yu-Jing Liang, Jing-Ping Yun
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-07-01
Series:	Frontiers in Immunology
Subjects:	interventional treatment PD-(L)1 inhibitor targeted therapy unresectable combined hepatocellular-cholangiocarcinoma outcome
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1591127/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Endobiliary radiofrequency ablation in recurrence and unresectable Perihilar cholangiocarcinoma
by: Apiwat Jareanrat, et al.
Published: (2025-07-01)

Successful radical surgical resection of initially unresectable intrahepatic cholangiocarcinoma by downsizing chemotherapy with gemcitabine plus cisplatin: a case report
by: Ryosuke Takayanagi, et al.
Published: (2017-11-01)

A pathological complete response to capecitabine plus oxaliplatin regimen combined with tislelizumab in advanced gastric cancer with liver metastases: A case report
by: Li-Ping Sheng, et al.
Published: (2024-12-01)

Combined treatment of unresectable hilar cholangiocarcinoma with subsequent liver transplantation
by: D. A. Granov, et al.
Published: (2022-04-01)

Analysis of risk factors of cholangiocarcinoma, role of diabetes mellitus and hepatitis B virus infection in the intrahepatic and extrahepatic cholangiocarcinoma: a retrospective case-based study in China
by: Hasan Md Rasadul, et al.
Published: (2025-07-01)

Deep learning-based CT radiomics predicts prognosis of unresectable hepatocellular carcinoma treated with TACE-HAIC combined with PD-1 inhibitors and tyrosine kinase inhibitors
by: Linan Yin, et al.
Published: (2025-01-01)

Lenvatinib combined with anti-PD-1 antibodies plus locoregional treatment for initial unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a multicenter real-world study
by: Qi-Yu Chi, et al.
Published: (2025-07-01)

The Combination of D-TACE-HAIC, Lenvatinib, and PD-1 Inhibitors Shows Significant Clinical Efficacy in Patients with Unresectable Hepatocellular Carcinoma
by: Wu Y, et al.
Published: (2025-02-01)

Hepatic artery infusion chemotherapy combined with camrelizumab and apatinib as conversion therapy for patients with unresectable hepatocellular carcinoma: a single-arm exploratory trial
by: Kugeluke Yalikun, et al.
Published: (2025-05-01)

Esophageal stenting for unresectable cancer (review of literature)
by: N. S. Popova, et al.
Published: (2021-01-01)

The use of Sirolimus for an unresectable and refractory venous malformation: A case series
by: Daniela Kristina Carolino, MD, et al.
Published: (2025-06-01)

The role of induction chemotherapy followed by surgery in unresectable stage IVb laryngeal and hypopharyngeal cancers: a case series
by: Pichit Sittitrai, et al.
Published: (2018-10-01)

Research progress of T cells in cholangiocarcinoma
by: Zhiming Wang, et al.
Published: (2025-02-01)

Neoadjuvant chemotherapy in technically unresectable carcinoma of external auditory canal
by: Amit Joshi, et al.
Published: (2015-01-01)

Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma
by: Emil Lou, et al.
Published: (2013-04-01)

Efficacy and safety outcomes of PD-1/PD-L1 inhibitors in recurrent cholangiocarcinoma: a real-world, multicenter and retrospective study
by: Lihui Lin, et al.
Published: (2025-07-01)

Development and Validation of Nomograms to Predict the Overall Survival and Progression-Free Survival in Patients with Advanced Unresectable Intrahepatic Cholangiocarcinoma
by: Xian F, et al.
Published: (2024-12-01)

Surgical treatment of peripheral hepatic cholangiocarcinoma with a visceral vein invasion
by: О. Yu. Usenko, et al.
Published: (2020-09-01)

Outcome prediction model for patients with unresectable hepatocellular carcinoma treated with targeted therapy
by: Qiang Ruan, et al.
Published: (2025-08-01)

LINC00313 promotes the aggressiveness and tumorigenesis of cholangiocarcinoma through targeting miR-320b and MITF
by: Ziyu Wang, et al.
Published: (2025-05-01)

Do Unresectable Giant Cell Tumors of Bone Treated With Denosumab Progress After Discontinuation of Treatment?
by: DENO Research Group, et al.
Published: (2025-01-01)

Cadonilimab, a PD-1/CTLA-4 bispecific antibody in unresectable hepatocellular carcinoma: a real-world study
by: Yilin Wang, et al.
Published: (2025-04-01)

EXPERIENCE OF USING COMBINATION OF RADIOSURGERY AND RESECTION OF THE LIVER IN PATIENTS WITH EXTENSIVE METASTATIC DESEASE
by: A. A. Zaykov, et al.
Published: (2016-02-01)

Cystatin B Promotes the Proliferation, Migration, and Invasion of Intrahepatic Cholangiocarcinoma
by: Dai Zhang, et al.
Published: (2025-01-01)

Physiogenomics in etiopathogenesis of cholangiocarcinoma
by: Beuy Joob, et al.
Published: (2017-01-01)

Meta-analysis of the efficacy of applying reduced surgery for the treatment of asymptomatic unresectable advanced gastric cancer
by: Xiong Li, et al.
Published: (2025-04-01)

Enhanced efficacy of immune checkpoint inhibitors combined locoregional therapy and tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma: A single - center retrospective study
by: Junfeng Bu, et al.
Published: (2025-02-01)

Establishment of a prognostic nomogram and risk stratification system for patients with combined hepatocellular-cholangiocarcinoma
by: Qiuhan Heng, et al.
Published: (2025-05-01)

Hepatic arterial infusion chemotherapy (HAIC) plus Lenvatinib and PD-1 inhibitors versus systemic chemotherapy for unresectable intrahepatic cholangiocarcinoma
by: Qingyu Xu, et al.
Published: (2025-05-01)

Surgical stage in sequential therapy of unresectable oral cancer T3-4bN0-3M0: evaluation of treatment results
by: Sh. I. Musin, et al.
Published: (2022-02-01)

Yttrium90-TARE with or without chemotherapy may improve survival in patients with locally advanced unresectable intrahepatic cholangiocarcinoma
by: Esteban Garita, et al.
Published: (2025-07-01)

Response to crizotinib in advanced intrahepatic cholangiocarcinoma with ZKSCAN1-MET fusion and MET amplification: case reports and literature review
by: Jian-Hui Wu, et al.
Published: (2025-06-01)

Association between ultrasound-based biliary and parenchymal intrahepatic mass-forming cholangiocarcinoma subtypes and clinicopathological features and survival
by: Cong-Jian Wen, et al.
Published: (2025-06-01)

Case Report: Long lasting response with TKI for combined hepatocellular-cholangiocarcinoma
by: Chiara Deiana, et al.
Published: (2025-03-01)

Phase II study of transcatheter arterial chemoembolization (TACE) combined with apatinib for advanced perihilar cholangiocarcinoma
by: Hao Li, et al.
Published: (2025-07-01)

Multiple cholangiocarcinomas in the intrahepatic and extrahepatic biliary tree due to dichloromethane exposure: a case report
by: Daisuke Ogawa, et al.
Published: (2020-04-01)

Circulating tumor DNA in cholangiocarcinoma: current clinical applications and future perspectives
by: Yi Wang, et al.
Published: (2025-07-01)

NEW OPPORTUNITIES FOR SURGICAL TREATMENT OF PATIENTS WITH INITIALLY UNRESECTABLE UTERINE CERVIX CANCE
by: I. A. Kosenko, et al.
Published: (2016-04-01)

Case report: Cancer-free survival after chemotherapy, targeted immunotherapy combination with proton therapy following space making technique in a patient with cholangiocarcinoma after choledochal cyst resection
by: Jian Kong, et al.
Published: (2025-01-01)

Establishment and characterization of CHC-X1: the third human combined hepatocellular–cholangiocarcinoma cell line
by: Huan Tang, et al.
Published: (2025-03-01)